FDA grants Breakthrough Therapy Designation to the company's drug for a rare, fatal pediatric disorder, paving the way for accelerated review and potential approval.
The multi-year partnership is expected to generate tens of billions in revenue, challenging Nvidia's market dominance.
Shares surged in after-hours trading after the company revealed positive results for its lead drug candidate, Telomir-1, in age-related studies.
Nimacimab monotherapy misses primary weight-loss endpoint, though combination with semaglutide shows promise, raising questions for the drug's future.
FDA grants Breakthrough Therapy status for a promising new drug targeting the rare and fatal Sanfilippo Syndrome Type B.
The strategic partnership for 6 gigawatts of GPU deployment challenges Nvidia's dominance and signals a new era in AI infrastructure.
The biotech firm secured its sixth approval for the ZORYVE franchise, expanding its dermatology treatment to children as young as two.
Taiwan Semiconductor hits a 52-week high while AMD and OpenAI announce a landmark chip deal, signaling sustained bullish momentum for chipmakers.